Company news

Neuren Pharmaceuticals Limited news in 2024

Neuren Pharmaceuticals Limited's news releases, calls and decks from 2024, newest first.

View company

Neuren announces A$50m on-market share buy-back program

November 13, 2024

Q3 2024 update

November 6, 2024

PRV sold for US$150m - Neuren to receive one third

November 5, 2024

DAYBUE receives marketing authorization in Canada

October 16, 2024

NEU continues PMS P3 preparations after positive FDA meeting

October 6, 2024

Phase 2 trial shows significant improvements in Angelman

August 9, 2024

Q2 2024 update

August 7, 2024

Phase 2 trial shows significant improvements in Pitt Hopkins

May 27, 2024

DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m

May 9, 2024

Q1 2024 quarterly activity and cash flow report

April 24, 2024

Trofinetide accepted for Priority Review by Health Canada

April 23, 2024

Neuren reports profit of $157 million for 2023

February 29, 2024

Appendix 4E and 2023 full year accounts

February 29, 2024

DAYBUE net sales US$87.1 million in Q4 2023

February 27, 2024

Comment on research report

February 16, 2024

Q4 2023 Appendix 4C Cash Flow Report

January 31, 2024

Q4 2023 quarterly activity report

January 31, 2024

Decks in 2024